glp 1 birth defects Glucagon-like peptide-1 receptor agonist use in pregnancy: a review GLP-1 receptor agonists, semaglutide, liraglutide,

And a small clinical trial in people with Alzheimers disease uncovered signs of slowed cognitive decline in those treated with the first generation GLP-1 drug liraglutide, Edisons team reports December 1 in Nature Medicine

Products that include Carnitine

Researchers could not identify either a minimum toxic dose or a lethal dose despite testing across a three-thousand-fold range of exposures

Do they have emergency procedures in place

Licensing (Marketing Authorisation): The MHRA has approved: Semaglutide (Wegovy) for adults with BMI 30 kg/m or BMI 27 kg/m with at least one weight-related comorbidity Liraglutide (Saxenda) with similar BMI criteria NHS Access (NICE Guidance): According to NICE guidance (TA664 for semaglutide), NHS-funded treatment is more restricted and typically available for adults with: BMI 35 kg/m with at least one weight-related comorbidity (such as hypertension, type 2 diabetes, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) For individuals from Black, Asian, and minority ethnic backgrounds, lower BMI thresholds may apply, recognising that these populations face increased metabolic risk at lower BMI levels